Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16791403 | 0.85 | BTK (0.52) | BTK | |
| SCHEMBL16766386 | 0.85 | BTK (0.41) | BTKMKNK1MKNK2SYKALDH1A1 | |
| SCHEMBL16766240 | 0.84 | BTK (0.53) | BTKMKNK1MKNK2SYKMAPK8 | |
| SCHEMBL16765813 | 0.82 | BTK (0.43) | BTK | |
| SCHEMBL16802706 | 0.82 | BTK (0.38) | BTKMKNK1MKNK2SYKMAPK8 | |
| SCHEMBL16791398 | 0.81 | BTK (0.37) | BTKMKNK1MKNK2SYKMAPK8 | |
| Hydrochloric Acid SCHEMBL16765882 | 0.81 | BTK (0.37) | BTKMKNK1MKNK2SYKMAPK8 | |
| SCHEMBL16790973 | 0.80 | BRD4 (0.37) | BTKMAPK8 | |
| SCHEMBL16790985 | 0.79 | BTK (0.35) | BTKLMNAMAPK8 | |
| SCHEMBL16766621 | 0.79 | BTK (0.37) | BTKSYKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077384-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | HOFFMANN LA ROCHE (CH) | 2017-09-06 | — | — | EP | disclosed |
| EP-3077384-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | HOFFMANN LA ROCHE (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2015082583-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | BTK, TYK2, LCK | BTK 1/4885TYK2 2/4885STAT3 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.